SCHEMBL4870658

SCHEMBL4870658

Nc1ccc(NC(=O)N2CCCCc3ccccc32)cc1

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.67
AVPR1A P37288 2/20 0.66
AVPR2 P30518 1/20 0.66
POLB P06746 3/20 0.65
TP53 P04637 3/20 0.64
NPC1 O15118 3/20 0.64
NFKB1 P19838 3/20 0.64
RAB9A P51151 3/20 0.64
NFKB2 Q00653 3/20 0.64
RELA Q04206 3/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
PKM P14618 2/20 0.64
THRB P10828 2/20 0.64
LMNA P02545 2/20 0.61
MEN1 O00255 1/20 0.60
HTT P42858 1/20 0.60
KMT2A Q03164 1/20 0.60
MAOB P27338 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867471 0.89 TP53 (0.81) MAPTPOLBTP53NPC1NFKB1
SCHEMBL4863076 0.88 MAPT (0.69) MAPTAVPR1APOLBTP53NPC1
SCHEMBL4869023 0.88 TP53 (0.78) MAPTPOLBTP53NPC1NFKB1
SCHEMBL4869800 0.87 MAPT (0.67) MAPTAVPR1AAVPR2POLBTP53
SCHEMBL4870106 0.87 MAPT (0.67) MAPTAVPR1AAVPR2POLBTP53
SCHEMBL4870684 0.87 MAPT (0.67) MAPTAVPR1APOLBTP53NPC1
SCHEMBL4871151 0.87 MAPT (0.67) MAPTAVPR1APOLBTP53NPC1
SCHEMBL4869602 0.87 MAPT (0.71) MAPTAVPR1AAVPR2POLBTP53
SCHEMBL4863126 0.87 POLB (0.83) MAPTAVPR1APOLBTP53NPC1
SCHEMBL4865198 0.86 MAPT (0.70) MAPTAVPR1APOLBTP53NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 MAPT 3398/4885AVPR1A 276/4885AVPR2 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.